Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia
SK Pasupuleti, K Chao, B Ramdas, R Kanumuri… - Molecular Therapy, 2023 - cell.com
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative neoplasm of
childhood. The molecular hallmark of JMML is hyperactivation of the Ras/MAPK pathway …
childhood. The molecular hallmark of JMML is hyperactivation of the Ras/MAPK pathway …
[HTML][HTML] Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism
X Chen, T Lu, M Ding, Y Cai, Z Yu, X Zhou… - Journal of Advanced …, 2023 - Elsevier
Introduction Epigenetic alterations play crucial roles in diffuse large B-cell lymphoma
(DLBCL). Disturbances in lipid metabolism contribute to tumor progression. However …
(DLBCL). Disturbances in lipid metabolism contribute to tumor progression. However …